Management of acute decompensated heart failure: Renal implications

Blood Purification

Volumn 26, Issue 1, 2008, Pages 18-22

  Virani, Sean A ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Gordon and Leslie Diamond Health Care Centre Vancouver Coastal Health   (Canada)

Author keywords

Acute decompensated heart failure; Congestive heart failure

Indexed keywords

GLYCERYL TRINITRATE; MILRINONE; NESIRITIDE; NITRATE; PLACEBO; VASODILATOR AGENT;

AWARENESS; CLINICAL TRIAL; CONFERENCE PAPER; DECOMPOSITION; DRUG DOSE TITRATION; DRUG MEGADOSE; HEART; HEART AFTERLOAD; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART PRELOAD; HUMAN; KIDNEY; KIDNEY FUNCTION; PRIORITY JOURNAL; TREATMENT OUTCOME; URINE VOLUME;

ACUTE DISEASE; CARDIOTONIC AGENTS; DIURETICS; HEART FAILURE; HEMOFILTRATION; HUMANS; KIDNEY; MYOCARDIAL CONTRACTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 38049048070     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110558     Document Type: Conference Paper

References (31)

1. American Heart Association: Heart Disease and Stroke Statistics - 2006 Update. Dallas, AHA, 2006.
2. Hunt SA, Abraham WT, Chin MH, et al: ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). American College of Cardiology website. Available: www.acc.org/ qualityandscience/clinical/guidelines/failure/ index.pdf (accessed July 31, 2007).
3. Heart Failure Society of America: HFSA 2006 comprehensive heart failure practice guidelines. Section 12: Evaluation and management of patients with acute decompensated heart failure. J Card Fail 2006;12:e86-e103.
4. Fonarow GC: The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003;4(suppl 7):S21-S30.
5. Cleland JG, Swedberg K, Follath F, et al: The EuroHeart failure survey programme - a survey on the quality of care among patients with heart failure in Europe, part 1: patient characteristics and diagnosis. Eur Heart J 2003;24:442-463.
6. Cuffe MS, Califf RM, Adams KF, et al: Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). JAMA 2002;287:1541-1547.
7. Gheorghiade M, Gattis WA, O'Connor CM, et al: Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004;291:1963-1971.
8. Gattis WA, O'Connor CM, Gallup DS, et al: Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol 2004;43:1534-1539.
9. Binanay C, Califf RM, Hasselblad V, et al: Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 2005;294:1625-1633.
10. Francis GS, Siegel RM, Goldsmith SR, et al: Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: activation of the neurohormonal axis. Ann Intern Med 1985;103:1-6.
11. Khan N, Ma I, Thompson C, et al: Kidney function and mortality among patients with left ventricular systolic dysfunction. J Am Soc Nephrol 2006;17:244-253.
12. Hillege HL, Nitsch D, Pfeffer MA, et al: Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006;113:671-678.
13. Fonarow GC, Adams KF, Abraham WT, et al: Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005;293:572-580.
14. Verma SP, Silke B, Hussain M, et al: First-line treatment of left ventricular failure complicating acute myocardial infarction: a randomized evaluation of immediate effects of diuretic, venodilator, arteriodilator and positive inotropic drugs on left ventricular function. J Cardiovasc Pharmacol 1987;10:38-46.
15. Emmerman CL, Marco TD, Costanzo MR, et al: Impact of intravenous diuretics on the outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. J Card Fail 2004;10:S116.
16. Lucas C, Johnson W, Hamilton MA, et al: Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J 2000;140:840-847.
17. Drazner MH, Rame JE, Stevenson LW, et al: Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med 2001;345:574-581.
18. Neuberg GW, Miller AB, O'Connor CM, et al: Diuretic resistance predicts mortality in patients with advanced heart failure: Prospective Randomized Amlodipine Survival Evaluation (PRAISE). Am Heart J 2002;1441:31-38.
19. Domanski M, Norman J, Pitt B, et al: Studies of left ventricular dysfunction. Diuretic use, progressive heart failure, and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 2003;42:705-708.
20. Bart BA, Boyle A, Bank AJ, et al: Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patient with Decompensated Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol 2005;46:2043-2046.
21. Costanzo MR, Guglin ME, Saltzberg MT, et al: Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007;49:675-683.
22. Gheorghiade M, Konstam MA, Burnett JC, et al: Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure. JAMA 2007;297:1332-1343.
23. Konstam MA, Gheorghiade M, Burnett JC, et al: Effects of oral tolvaptan in patients hospitalized for worsening heart failure. JAMA 2007;297:1319-1331.
24. Burnett JC, Smith WB, Ouyang J, et al: Tolvaptan (OPC-41061), a V2 vasopressin receptor antagonist, protects against the decline in renal function observed with loop diuretic therapy. J Card Fail 2003;9:36.
25. Elkayam U, Bitar F, Akhter MW, et al: Intravenous nitroglycerin in the treatment of decompensated heart failure: potential benefits and limitations. J Cardiovasc Pharmacol Ther 2004;9:227-241.
26. Publication Committee for the VMAC Investigators: Intravenous nesiritide versus nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531-1540.
27. Abraham WT, Lowes BD, Ferguson DA, et al: Systemic haemodynamic, neurohormonal and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998;4:37-44.
28. Mills RM, LeJemtel TH, Horton DP, et al: Sustained haemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol 1999;34:155-162.
29. Sackner-Bernstein JD, Kowalski M, Fox M, et al: Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled-trials. JAMA 2005;293:1900-1905.
30. Sackner-Bernstein JD, Skopicki HA, Aaronson KD: Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111:1487-1491.
31. Abraham WT, Adams KF, Fonarow GC, et al: In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005;46:57-64.